

Updates In Hematology and Hematologic Malignancies 2019

FRI, MARCH 22
8am-4:30pm
Omni Charlottesville Hotel

Program Overview

This program will explore research and advances in the diagnosis and management of benign hematologic conditions and hematologic malignancies, including indications for novel therapies and use in special populations. Aimed at community hematologists and oncologists, as well as advanced practice providers and nurses, this meeting will use case-based presentations to highlight recommendations for treatment of common hematologic diagnoses such as myelodysplastic syndromes, myeloproliferative neoplasms, and immune thrombocytopenia. We will also discuss pain management in the era of opioid addiction.

Learning Objectives

As a result of participation in this symposium, attendees will be able to:

- Discuss alternative treatment regimens available for patients who have failed first line therapy for ITP
- Describe clinical scenarios in which reversal of anticoagulation is indicated and how reversal agents should be administered
- Recognize patient populations for whom eltrombopag should be added to immunosuppressive therapy for treatment of aplastic anemia.
- Explain a differential diagnosis for thrombocytopenia in the pregnant patient.
- Develop a treatment strategy using targeted therapies for cutaneous T cell lymphoma.
- Describe management of side effect profile for new agents and for targeted therapies.

Course Directors

Karen Ballen, MD

Professor of Medicine, Section Chief for Hematologic Malignancy and Stem Cell Transplant

Hillary Maitland, MD, MS

Assistant Professor of Medicine

Special Guest Faculty

Adam Cuker, MD, MS

Director, Penn Comprehensive Hemophilia and Thrombosis Program, University of Pennsylvania

Dr. Cuker is the associate director of clinical research at the Penn-CHOP Blood Center for Patient Care and Discovery. He has served as co-chair of the ASH Quality Task Force, and currently serves on the ASH Committee on Quality

Ruben Mesa, MD

Professor of Medicine; Director, Mays Cancer Center, UT Health San Antonio

Dr. Mesa is Director of the UT Health San Antonio Cancer Center and Mays Family Foundation Distinguished University Presidential Chair. He has been involved in MPN research for more than 20 years and led development of the NCCN guideline on the diagnosis and treatment of myelofibrosis, polycythemia vera, and essential thrombocythemia. Dr. Mesa has been the principal investigator or co-principal investigator of more than 70 clinical trials.

UVA Faculty

Leslie Blackhall, MD

Associate Professor of Medicine; Section Head, Palliative Medicine

Kelly Davidson, MD

Assistant Professor of Medicine

Michael Douvas, MD

Associate Professor of Medicine

Michael K Keng, MD

Assistant Professor of Medicine

Lee Ann Klemptner, RN, BSN, CHPN

Care Coordinator, Emily Couric Cancer Center

Kimberly Leake, MSN NP-C

Heme Malignancy NP, Emily Couric Cancer Center

Daniel W (Trey) Lee

Assistant Professor of Medicine, Director of Pediatric Stem Cell Transplant

Thomas P Loughran, Jr, MD

F. Palmer Weber-Smithfield Foods Professor of Oncology Research and Professor of Medicine; Director, UVA Cancer Center

Louise Man, MD

Assistant Professor of Medicine

Craig A Portell, MD

Assistant Professor of Medicine

Michael E Williams, MD, ScM

Byrd S. Leavell Professor of Medicine and Professor of Pathology; Chief, Hematology/Oncology Division; Physician Lead, UVA Cancer Service Line

Planning Committee

Gina DeGennaro, DNP, RN, CNS, AOCN

Associate Professor of Nursing

Elizabeth Patterson, MEd

CME Program Manager

AGENDA

8:00 - 8:30	Breakfast and Registration	
8:30 - 8:35	Intro and Welcome	Loughran/Maitland
8:35 - 10:25	Hemostasis	
8:35	Anticoagulant Monitoring and Reversal	Maitland
9:00	Hematologic Complications of Pregnancy	Man
9:25	Updates in Treatment of Refractory ITP	Cuker
10:10	Panel	Maitland, Man, Cuker
10:25 - 10:40	Break	
10:40 - 12:35	Malignancy	
10:40	Cutaneous T cell Lymphoma	Portell
11:05	CAR T cell Therapies	Lee
11:30	Updates on Hodgkins Therapy	Douvas
11:55	Follicular Lymphoma Management	Williams
12:20	Panel	Portell, Lee, Douvas, Williams, Leake
12:35 - 1:15	Lunch	
1:15 - 2:15	Palliative Care	
1:15	Pain Management in the Era of Opioid Dependence	Blackhall, Klemptner
2:00	Panel	Blackhall, Klemptner, PharmD
2:15 - 4:20	Bone Marrow Failure/ Myeloid Malignancy	
2:15	Update on the Diagnosis and Management of Antiphospholipid Syndrome	Davidson
2:40	Myelodysplastic Syndrome	Keng
3:05 - 3:20	Break	
3:20	Myeloproliferative Disorders	Mesa
4:05	Panel	Davidson, Keng, Mesa, Ballen
4:20 - 4:30	Closing	Maitland, Ballen

Registration and Fees

Online registration available at www.cmevillage.com

Registration fees (including online syllabus, breakfast, lunch, and break refreshments) Early bird fees apply until February 1, 2019

- Physicians \$195 (\$220 after 2/1/19)
- NPs, PAs, Nurses, Fellows, & Other Health Professionals \$75 (\$95 after 2/1/19)

Online registration closes 3/10/19. Walk-in registration subject to a \$100 late fee.

*Syllabus will be provided online at www.cmevillage.com

Confirmation and Cancellation Policy

Upon receipt of registration and payment, you will receive an email confirmation and EPay receipt. Please keep this confirmation for your records. Registration fees will be refunded (less a \$50 administrative fee) for written email cancellations received a minimum of 14 days prior to the activity date. No refunds may be granted for cancellations made within 13 days of the activity.

www.cmevillage.com

Accreditation and Designation Statements

The University of Virginia School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Virginia School of Medicine designates this live activity for a maximum of *6.25 AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Virginia School of Medicine, as an accredited provider, awards 6.25 hours of participation (consistent with the designated number of *AMA PRA Category 1 Credits™*) to participants who successfully complete this educational activity. The University of Virginia School of Medicine maintains a record of participation for six (6) years.

The University of Virginia School of Nursing Continuing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

The University of Virginia SONCE awards *6.25 contact hours* for nurses who participate in this educational activity and complete the post activity evaluation.

Successful completion of this CME activity enables the participant to earn up to 6.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

The Omni Hotel

Rooms are available at a special nightly rate of \$219 + taxes/fees. Call 1-800-THE-OMNI (1-800-843-6664) and mention the group code "Updates in Hematology" or reserve online with the link below.

Block closes on February 20, 2019.

Parking is complimentary for overnight guests or \$3/day with voucher.

www.omnihotels.com

Contact Information

Elizabeth K Patterson, MEd
Program Manager, Office of
Continuing Medical Education
epatterson@virginia.edu
434-924-5310